Anavex Life Sciences Corp.
AVXL Nasdaq
SEC CIK 1314052
Follow Anavex Life Sciences Corp.
Weekly email: filings, results
Net income
$7.8M
+159.1% vs same quarter last year
EPS, diluted
$0.08
+150% vs same quarter last year
Operating cash flow
−$9.1M
+27% vs same quarter last year
Operating income
$6.7M
+146.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$46.4M |
| FY24 | −$43M |
| FY23 | −$47.5M |
| FY22 | −$48M |
| FY21 | −$37.9M |
| FY20 | −$26.3M |
| FY19 | −$26.3M |
| FY18 | −$17.3M |
| FY17 | −$13.5M |
| FY16 | −$14.7M |
| FY15 | −$12.1M |
| FY14 | −$10M |
| FY13 | −$3.7M |
| FY12 | −$8.3M |
| FY11 | −$7.3M |